Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil

NCT07759804 is registered in ClinicalTrials.gov with Liquidia Technologies, Inc. as lead sponsor.

NCT NCT07759804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07759804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil
Lead sponsor
Liquidia Technologies, Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)